AKT1 and lung cancer: Treatment of a mouse lung cancer model with indirubin‐3‐monoxime and TQ (5, 10, 10 mg/kg) significantly reduced the expression of Phospho‐Akt (p‐AKT), Phospho‐Mammalian target of rapamycin (p‐mTOR), Cas‐3, p‐53 and NF‐κB.58